Tap to start →
Photo: Laurynas Me / Unsplash
1 / 3
Mazdutide is a weekly glucagon and GLP-1 dual agonist approved in China in 2025 for weight management. It is not approved by the FDA in the US.
2 / 3
Mazdutide was discovered by Eli Lilly and licensed to Innovent Biologics for China.
3 / 3
A drug approved in another country is still unapproved in the US, and US products sold under its name carry real quality risks.
Mazdutide is a weekly glucagon and GLP-1 dual agonist approved in China in 2025 for weight management. It is not approved by the FDA in the US.
Tap below for the full page. Not medical advice; talk to your clinician about your care.